Managing severe epilepsy syndromes of early childhood

Journal of Child Neurology

Volumn 24, Issue 8, 2009, Pages

  Wheless, James W ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antiepileptic drugs; Children; Doose syndrome; Dravet syndrome; Epilepsy; Ketogenic diet; Lennox Gastaut syndrome; Treatment; Vagus nerve stimulation

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; ANTIPYRETIC AGENT; BROMIDE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CORTICOTROPIN; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; MESUXIMIDE; NITRAZEPAM; PHENYTOIN; PLACEBO; RUFINAMIDE; STEROID; STIRIPENTOL; SULTIAME; TIAGABINE; TOPIRAMATE; VACCINE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; GLUCOSE; SACCHARIN;

ABSENCE; ADD ON THERAPY; ANOREXIA; ARTICLE; ATONIC SEIZURE; CLINICAL TRIAL; COMMON COLD; CORPUS CALLOSUM TRANSSECTION; COST EFFECTIVENESS ANALYSIS; COUGHING; DECREASED APPETITE; DOSE RESPONSE; DRAVET SYNDROME; DROP ATTACK; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EPILEPTIC STATE; FEVER; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; LOW DRUG DOSE; MYOCLONIC ASTATIC EPILEPSY; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; ONSET AGE; PRIORITY JOURNAL; RASH; SEIZURE; SIDE EFFECT; SOMNOLENCE; THROMBOCYTE COUNT; TONIC CLONIC SEIZURE; TONIC SEIZURE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION; VIRUS INFECTION; VOICE CHANGE; VOMITING; WEIGHT GAIN; ADJUVANT THERAPY; CHILD; COGNITION; CORPUS CALLOSOTOMY; DISEASE CONTROL; DOOSE SYNDROME; DRUG ERUPTION; DRUG SAFETY; DYSPHONIA; FEBRILE CONVULSION; GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS; HEALTH CARE COST; KETOACIDOSIS; LONG TERM CARE; MENTAL DEFICIENCY; MONOTHERAPY; MYOCLONUS; NEUROSURGERY; QUALITY OF LIFE; SEVERE MYOCLONIC EPILEPSY BORDERLINE; STEROID THERAPY; TREATMENT RESPONSE;

AGE FACTORS; ANTICONVULSANTS; BRAIN; CHILD, PRESCHOOL; ELECTRIC STIMULATION THERAPY; EPILEPSY; HUMANS; INFANT; KETOGENIC DIET; NEUROSURGICAL PROCEDURES; PATIENT CARE TEAM; SYNDROME;

EID: 68549135272     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073809338153     Document Type: Article

References (55)

1. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of epilepsies in children and young people: A national clinical guideline. 2005. http://www.sign.ac.uk/pdf/sign81.pdf. Accessed January 1, 2009.
2. Arzimanoglou A., French J., Blume WT, et al. Lennox-Gastaut syndrome: A consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82-93.
3. Wheless JW Nonpharmacologic treatment of the catastrophic epilepsies of childhood. Epilepsia. 2004;45(suppl 5):17-22.
4. Wheless JW, Sankar R. Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia. 2003;44(suppl 11):27-37.
5. Hurst DL Severe myoclonic epilepsy of infancy. Pediatr Neurol. 1987;3(5):269-272.
6. Dravet C. Severe myoclonic epilepsy in infants and its related syndromes. Epilepsia. 2000;41(suppl 9):7.
7. Stephani U. The natural history of myoclonic astatic epilepsy (Doose Syndrome) and Lennox-Gastaut syndrome. Epilepsia. 2006;47(suppl 2):53-55.
8. Kassaï B., Chiron C., Augier S., et al. Severe myoclonic epilepsy in infancy: A systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49(2):343-348.
9. Chiron C., Marchand MC, Tran A., et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomized placebo-controlled syndrome dedicated trial. STICLO study group. Lancet. 2000;356(9242):1638-1642.
10. Thanh TN, Chiron C., Dellatolas G., et al. Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome). Arch Pediatr. 2002;9(11):1120-1127.
11. Striano P., Coppola A., Pezzella M., et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;69(3):250-254.
12. Nieto-Barrera M., Candau R., Nieto-Jimenez M., Correa A., del Portal LR Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9(8):590-594.
13. Mikaeloff Y., de Saint-Martin A., Mancini J., et al. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res. 2003;53(3):225-232.
14. Kröll-Seger J., Portilla P., Dulac O., Chiron C. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics. 2006;37(6):325-329.
15. Korff C., Laux L., Kelley K., Goldstein J., Koh S., Nordli D. Jr. Dravet syndrome (severe myoclonic epilepsy in infancy): A retrospective study of 16 patients. J Child Neurol. 2007;22(2):185-194.
16. Grosso S., Franzoni E., Iannetti P., et al. Efficacy and safety of topiramate in refractory epilepsy of childhood: Long-term follow-up study. J Child Neurol. 2005;20(11):893-897.
17. Oguni H., Hayashi K., Oguni M., et al. Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant. Epilepsia. 1994;35(6):1140-1145.
18. Caraballo RH, Fejerman N. Dravet syndrome: A study of 53 patients. Epilepsy Res. 2006;70(suppl 1):S231-S238.
19. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: Expert Opinion, 2005. J Child Neurol. 2005;20(suppl 1):S1-S56.
20. Dravet C., Bureau M., Oguni H., Fukuyama Y., Cokar O. Severe myoclonic epilepsy in infancy (Dravet syndrome). In: Roger J, Bureau M, Dravet C, et al., eds. Epileptic Syndromes in Infancy, Childhood, and Adolescence. 3rd ed. London, England: John Libbey; 2002:81-103.
21. Guerrini R., Aicardi J. Epileptic encephalopathies with myoclonic seizures in infants and children (severe myoclonic epilepsy and myoclonic-astatic epilepsy). J Clin Neurophysiol. 2003;20(6):449-461.
22. Perucca E., Gram L., Avanzini G., Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998;39(1):5-17.
23. Gayatri NA, Livingston JH Aggravation of epilepsy by antiepileptic drugs. Dev Med Child Neurol. 2006;48(5):394-398.
24. Doose H. Myoclonic astatic epilepsy of early childhood. In: Roger J, Dravet C, Bureau M, Dreifuss FE, Perret A, Wolf P, eds. Epileptic Syndromes in Infancy, Childhood, and Adolescence. 2nd ed. London, England: John Libbey; 1992:103-114.
25. Kilaru S., Bergqvist AG Current treatment of myoclonic astatic epilepsy: clinical experience at the Children's Hospital of Philadelphia. Epilepsia. 2007;48(9):1703-1707.
26. Oguni H., Tanaka T., Hayashi K., et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics. 2002;33(3):122-132.
27. Doose H., Baier WK Epilepsy with primarily generalized myoclonic-astatic seizures: A genetically determined disease. Eur J Pediatr. 1987;146(6):550-554.
28. Ramos-Platt LMK, Zupanc ML, Hecox K., et al. Felbamate as an effective treatment in myoclonic astatic epilepsy of Doose: A report on 8 patients. Epilepsia. 2008;49(suppl 7):92-93.
29. Covanis A., Gupta AK, Jeavons PM Sodium valproate: Mono-therapy and polytherapy. Epilepsia. 1982;23(6):693-720.
30. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox Gastaut Syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome. N Engl J Med. 1993;328(1):29-33.
31. Sachdeo RC, Glauser TA, Ritter F., et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. 1999;52(9):1882-1887.
32. Motte J., Trevathan E., Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med. 1997;337(25):1807-1812.
33. Dodson WE Felbamate in the treatment of Lennox-Gastaut Syndrome: Results of a 12-month open-label study following a randomized clinical trial. Epilepsia. 1993;34(suppl 7):S18-S24.
34. Pellock JM, Faught E., Leppik IE, Reife R., Lim P., Pledger G. Felbamate: Consensus of current clinical experience. Epilepsy Res. 2006;71(2-3):89-101.
35. Glauser TA, Levisohn PM, Ritter F., Sachedo RC Topiramate in Lennox-Gastaut syndrome: Open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia. 2000;41(suppl 1):S86-S90.
36. Glauser T., Kluger G., Sachdeo R., et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70(21):1950-1958.
37. Deeks ED, Scott LJ Rufinamide. CNS Drugs. 2006;20(9):751-760; discussion 761.
38. Conry J., Ng Y., Collins S., et al. Clobazam in the treatment of Lennox-Gastaut syndrome [published online ahead of print December 15, 2008]. Epilepsia. DOI: 10.1111/j.1528-1167. 2008.01935.x.
39. Kossoff EH, Zupec-Kania BA, Amark PE, et al, for The Charlie Foundation, and the Practice Committee of the Child Neurology Society. Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group. Epilepsia. 2009;50(2):304-317.
40. Freeman JM, Vining EP Seizures decrease rapidly after fasting: preliminary studies of the ketogenic diet. Arch Pediatr Adolesc Med. 1999;153(9):946-949.
41. Freeman JM, Vining EP, Kossoff EH, et al. A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia. 2009;50(2):322-325.
42. Frost M., Gates J., Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia. 2001;42(9):1148-1152.
43. Aldenkamp AP, Majoie HJ, Berfelo MW, et al. Long-term effects of 24-month treatment with vagus nerve stimulation on behaviour in children with Lennox-Gastaut syndrome. Epilepsy Behav. 2002;3(5):475-479.
44. Aldenkamp AP, Van de Veerdonk SH, et al. Effects of 6 months of treatment with vagus nerve stimulation on behavior in children with Lennox-Gastaut syndrome in an open clinical and nonrandomized study. Epilepsy Behav. 2001;2(4):343-350.
45. Majoie HJ, Berfelo MW, Aldenkamp AP, Evers SM, Kessels AG, Renier WO Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut Syndrome: Clinical results, neuropsychological effects, and cost-effectiveness. J Clin Neurophysiol. 2001;18(5):419-428.
46. Rougier A., Claverie B., Pedespan JM, Marchal C., Loiseau P. Callosotomy for intractable epilepsy: Overall outcome. J Neurosurg Sci. 1997;41(1):51-57.
47. You SJ, Kang HC, Ko TS, et al. Comparison of corpus callosotomy and vagus nerve stimulation in children with Lennox-Gastaut syndrome. Brain Dev. 2008;30(3):195-199.
48. Cukiert A., Burattini JA, Mariani PP, et al. Extended, one-stage callosal section for treatment of refractory secondarily generalized epilepsy in patients with Lennox-Gastaut and Lennox-like syndromes. Epilepsia. 2006;47(2):371-374.
49. Conry JA Pharmacologic treatment of the catastrophic epilepsies. Epilepsia. 2004;45(suppl 5):12-16.
50. Gayatri NA, Livingston JH Aggravation of epilepsy by anti-epileptic drugs. Dev Med Child Neurol. 2006;48(5):394-398.
51. Perucca E., Gram L., Avanzini G., Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998;39(1):5-17.
52. Kassaï B., Chiron C., Augier S., et al. Severe myoclonic epilepsy in infancy: A systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49(2):343-348.
53. Hurst DL Severe myoclonic epilepsy of infancy. Pediatr Neurol. 1987;3(5):269-272.
54. Chiron C., Marchand MC, Tran A., et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomized placebo-controlled syndrome dedicated trial. STICLO study group. Lancet. 2000;356(9242):1638-1642.
55. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: Expert Opinion, 2005. J Child Neurol. 2005;20(suppl 1):S1-S56.